Hypoxia Increases Tumor Cell Shedding of MHC Class I Chain-Related Molecule: Role of Nitric Oxide
Open Access
- 15 June 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (12), 4746-4753
- https://doi.org/10.1158/0008-5472.can-08-0054
Abstract
The MHC class I chain-related (MIC) molecules play important roles in tumor immune surveillance through their interaction with the NKG2D receptor on natural killer and cytotoxic T cells. Thus, shedding of the MIC molecules from the tumor cell membrane represents a potential mechanism of escape from NKG2D-mediated immune surveillance. Tumor hypoxia is associated with a poor clinical outcome for cancer patients. We show that hypoxia contributes to tumor cell shedding of MIC through a mechanism involving impaired nitric oxide (NO) signaling. Whereas hypoxia increased MIC shedding in human prostate cancer cells, activation of NO signaling inhibited hypoxia-mediated MIC shedding. Similar to incubation in hypoxia, pharmacologic inhibition of endogenous NO signaling increased MIC shedding. Parallel studies showed hypoxia-mediated tumor cell resistance to lysis by interleukin 2–activated peripheral blood lymphocytes (PBL) and NO-mediated attenuation of this resistance to lysis. Inhibition of NO production also led to resistance to PBL-mediated lysis. Interference of MIC-NKG2D interaction with a blocking anti-MIC antibody abrogated the effect of hypoxia and NO signaling on tumor cell sensitivity to PBL-mediated lysis. Finally, continuous transdermal delivery of the NO mimetic glyceryl trinitrate (7.3 μg/h) attenuated the growth of xenografted MIC-expressing human prostate tumors. These findings suggest that the hypoxic tumor microenvironment contributes to resistance to immune surveillance and that activation of NO signaling is of potential use in cancer immunotherapy. [Cancer Res 2008;68(12):4746–53]Keywords
This publication has 33 references indexed in Scilit:
- Hypoxia-driven selection of the metastatic phenotypeCancer and Metastasis Reviews, 2007
- Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide SignalingClinical Cancer Research, 2007
- Release of MICB Molecules by Tumor Cells: Mechanism and Soluble MICB in Sera of Cancer PatientsHuman Immunology, 2006
- Proteolytic Release of Soluble UL16-Binding Protein 2 from Tumor CellsCancer Research, 2006
- Nitric oxide signalling and cellular adaptations to changes in oxygenationToxicology, 2005
- Nitric oxide‐mediated regulation of hypoxia‐induced B16F10 melanoma metastasisInternational Journal of Cancer, 2003
- Oxygenation status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapySeminars in Oncology, 2001
- Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICAScience, 1999
- Hypoxia‐induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitroInternational Journal of Cancer, 1994
- Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells.The Journal of Experimental Medicine, 1985